Heptares bags GPCR tech in $12M G7 buyout; Pfizer reports PhIII success for Herceptin biosim
London-based Heptares has struck a deal to buy Switzerland’s G7 Therapeutics for about $12 million. Heptares was lured to the deal by G7’s expertise …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
